Dc3 Therapeutics LLC is categorized under Commercial Biotechnical Research in South San Francisco, CA and active since 2013.
Dc3 Therapeutics LLC was established in 2013, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Jonathan Wray at the company’s single location by writing to 160 South Linden Avenue # 130, South San Francisco, California CA 94080 or by phoning (650) 449-1372. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Dc3 Therapeutics LLC |
| Contact Person: | Jonathan Wray |
| Address: | 160 South Linden Avenue # 130, South San Francisco, California 94080 |
| Phone Number: | (650) 449-1372 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2013 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Dc3 Therapeutics LLC was started in 2013 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Jonathan Wray for inquiries that concern Dc3 Therapeutics LLC by calling the company number (650) 449-1372, as your correspondence is most welcome. Additionally, the physical location of the single location of Dc3 Therapeutics LLC can be found at the coordinates 37.642274,-122.413624 as well as the street address 160 South Linden Avenue # 130 in South San Francisco, California 94080.
For its online presence, you may visit Dc3 Therapeutics LLC’s website at and engage with its social media outlets through on Twitter and on Facebook.